Saol

Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial

Retrieved on: 
Tuesday, September 19, 2023
Osteoarthritis, University, Saol, Pharmacokinetics, COMPASS, Physical medicine and rehabilitation, Associate, Rehabilitation, RAISE, Neuroanatomy, MD, Patient, Phase, Therapy, Chronic pain, Safety, Knee, Birth control, Pharmaceutical industry, Nursing

ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 19, 2023 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that enrollment has been completed in the company's two Phase II trials for SL-1002. 

Key Points: 
  • Topline data for the COMPASS Osteoarthritis Knee Pain Trial will be available in the first quarter of 2024, with topline data from the RAISE Limb Spasticity Trial available shortly thereafter.
  • Topline data for the COMPASS Osteoarthritis Knee Pain Trial will be available in the first quarter of 2024.
  • Both the COMPASS Osteoarthritis Knee Pain Trial ( NCT05470608 ) and the RAISE Limb Spasticity Trial ( NCT05311215 ) are each fully enrolled, at 132 patients and 32 patients, respectively.
  • Saol Therapeutics currently expects topline results for the COMPASS Osteoarthritis Knee Pain Trial in the first quarter of 2024, and the RAISE Limb Spasticity Trial in the second quarter of 2024.

Saol Therapeutics and InformedDNA Partner to Offer Genetic Counseling to Patients with Rare Mitochondrial Disease

Retrieved on: 
Tuesday, April 26, 2022
CEO, Pain management, Clinical trial, Degenerative disease, Pivotal, Genetics, Phase, Genomics, University, Caregiver, PDC, Learning, Congenital lactic acidosis, Patient, Genetic counseling, Topical steroid withdrawal, Sail, Spasticity, Review, Lists of diseases, Saol, Clinical Trial Service Unit, CLA, Solution, Mitochondrial disease, Health care, Pyruvate dehydrogenase complex, DCA, FDA, Disease, Partnership, Precision medicine, Therapy, Pharmaceutical industry, Medicine

ROSWELL, Ga. and ST. PETERSBURG, Fla., April 26, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a partnership with InformedDNA®, the nation's leading applied genomics solutions company, to offer genetic counseling for the families of individuals with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD).  The counseling will also review potential participation in a Phase 3 clinical trial. PDCD affects less than 300 children in the United States annually and lacks any FDA-approved treatment.

Key Points: 
  • After speaking with a genetic counselor, families interested in learning more about the clinical research study will be connected with a trial site.
  • Dave Penake, CEO of Saol Therapeutics, is pleased to partner with InformedDNA to provide this valuable service.
  • Healthcare providers and caregivers for children with Pyruvate Dehydrogenase Complex Deficiency (PDCD) may request a genetic counseling appointment by visiting www.InformedDNA/Saol .
  • Saol Therapeutics (pronounced "Sail") is a privately held, biopharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda.

Amneal Expands Injectables Portfolio with 4 New Products

Retrieved on: 
Thursday, February 17, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NYSE, Patient, Food, Risk, Carboprost, Company, Federation, CGT, Weather, Injection, Forward-looking statement, Medication, U.S. Securities and Exchange Commission, Security (finance), Baclofen, Annual report, Degenerative disease, SVP, Regulation of tobacco by the U.S. Food and Drug Administration, Tris, Abbreviated New Drug Application, USP, FDA, Saol, Generic, ANDA, Central nervous system, LVP, Private Securities Litigation Reform Act, Growth, Dexamethasone, Research, Investment, Amneal Pharmaceuticals, COVID-19, Azacitidine, Atropine, Peptide, Pharmaceutical industry, Fine chemical, Generic drug, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.
  • An important element of Amneals long-term growth strategy is expanding our injectables business, and todays announcement of four new approvals is another key step.
  • The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars.
  • In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs.